Liver transplant patients may cut lifelong drugs with simple ultrasound test

This study tests whether a special ultrasound called a fibroscan can help doctors safely lower the dose of anti-rejection drugs in liver transplant recipients. Participants must be at least 2 years post-transplant, have normal liver blood tests, and not have autoimmune liver disease or recent rejection. The goal is to reduce drug doses by 30% without causing rejection, which could lower side effects like kidney problems, diabetes, and cancer.